The genetic basis for measles vaccine failure

被引:15
作者
Jacobson, RM
Poland, GA
机构
[1] Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Program Translat Immunovirol & Biodef, Rochester, MN 55905 USA
[4] Mayo Clin & Mayo Fdn, Mayo Vaccine Res Grp, Rochester, MN 55905 USA
关键词
genetics; measles; measles vaccine; population; variation (genetics);
D O I
10.0180/08035320310021246
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The US measles epidemics of 1989-1991 included a series of outbreaks resulting from vaccine failure. A series of studies was launched aimed Lit elucidating the mechanisms of this vaccine failure. A meta-analysis of the literature examining epidemics in vaccinated populations was conducted, which showed that the secondary vaccine failure rate (development of the disease despite an initial or primary vaccine success) is no more than 0.2%. The overwhelming proportion of measles vaccine failure was due to primary vaccine failure (failure to ever generate antibody from antigenic stimulation). This comparison of two geographically distinct communities revealed that 10% of children previously vaccinated against measles lacked antibody on follow-up and that these vaccine failures clustered in families. A Study of monozygotic and dizygotic twins revealed a high degree of heritability of measles vaccine antibody level. Subsequent Studies found associations with both class I and class II alleles in these population-based studies. In the future, detection of the specific peptides that interact with human leukocyte antigen (HLA) molecules may serve as the basis for improved vaccines and address vaccine failure that results from cold-chain problems, immaturity of the immune system, malnutrition and maternal immunity.
引用
收藏
页码:43 / 46
页数:4
相关论文
共 16 条
[1]   Secondary failure rates of measles vaccines: A metaanalysis of published studies [J].
Anders, JF ;
Jacobson, RM ;
Poland, GA ;
Jacobsen, SJ ;
Wollan, PC .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (01) :62-66
[2]   Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination [J].
Bautista-López, N ;
Ward, BJ ;
Mills, E ;
McCormick, D ;
Martel, N ;
Ratnam, S .
VACCINE, 2000, 18 (14) :1393-1401
[3]   ANTIBODY-RESPONSE FOLLOWING MEASLES-MUMPS-RUBELLA VACCINE UNDER CONDITIONS OF CUSTOMARY USE [J].
BRUNELL, PA ;
WEIGLE, K ;
MURPHY, MD ;
SHEHAB, Z ;
COBB, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1983, 250 (11) :1409-1412
[4]  
*CDCP, 1992, MMWR-MORBID MORTAL W, V41, P109
[5]  
*CDCP, 1993, MMWR-MORBID MORTAL W, V42, P378
[6]  
Hayney M S, 1998, Int J Infect Dis, V2, P143, DOI 10.1016/S1201-9712(98)90116-3
[7]  
Hayney MS, 1996, J INVEST MED, V44, P261
[8]   The association of class IHLA alleles and antibody levels after a single dose of measles vaccine [J].
Jacobson, RM ;
Poland, GA ;
Vierkant, RA ;
Pankratz, VS ;
Schaid, DJ ;
Jacobsen, SJ ;
St Sauver, J ;
Moore, SB .
HUMAN IMMUNOLOGY, 2003, 64 (01) :103-109
[9]   Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: Failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR [J].
Mitchell, LA ;
Tingle, AJ ;
Decarie, D ;
Lajeunesse, C .
CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 1998, 89 (05) :325-328
[10]  
Orenstein W A, 1986, Dev Biol Stand, V65, P75